• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Officer Moatazedi David sold $1,370,249 worth of shares (103,376 units at $13.26), decreasing direct ownership by 17% to 514,870 units (SEC Form 4)

    3/20/25 6:27:04 PM ET
    $EOLS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EOLS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    X
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    MOATAZEDI DAVID

    (Last) (First) (Middle)
    520 NEWPORT CENTER DR.
    SUITE 1200

    (Street)
    NEWPORT BEACH CA 92660

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Evolus, Inc. [ EOLS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    See Remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    03/18/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 03/18/2025 S(1) 103,376 D $13.255(2) 514,870 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain Restricted Stock Units.
    2. The shares were sold in multiple trades at prices ranging from $13.1765 to $13.256. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
    Remarks:
    /s/ Jeffrey J. Plumer, as attorney-in-fact for David Moatazedi 03/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $EOLS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EOLS

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    BTIG Research
    1/29/2024$10.00 → $16.00Equal Weight → Overweight
    Barclays
    6/23/2022$18.00Buy
    Needham
    5/12/2022$8.00 → $10.00Underweight → Equal Weight
    Barclays
    1/20/2022$11.00Hold → Buy
    Truist
    11/3/2021$22.00 → $15.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EOLS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Evolus Reports First Quarter 2025 Results

      Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

      5/7/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility

      Refinanced Existing Credit Facility Drawing $150 Million at Close with $100 Million of Strategic Incremental Capacity Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has entered into an amended and restated credit facility, replacing its existing $125 million credit agreement with a new $250 million credit facility with funds managed by Pharmakon Advisors, LP. Highlights of the new facility include: Lowered Interest Rate: Reduced borrowing cost by 350 basis points (bps) based on current interest rates. The facility will mature five years from the funding date. Interest will be paid quarterly

      5/5/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus to Report First Quarter Financial Results on May 7, 2025

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

      4/23/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Evolus with a new price target

      BTIG Research initiated coverage of Evolus with a rating of Buy and set a new price target of $21.00

      4/17/25 8:32:06 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus upgraded by Barclays with a new price target

      Barclays upgraded Evolus from Equal Weight to Overweight and set a new price target of $16.00 from $10.00 previously

      1/29/24 7:09:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham initiated coverage on Evolus with a new price target

      Needham initiated coverage of Evolus with a rating of Buy and set a new price target of $18.00

      6/23/22 7:38:38 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Financials

    Live finance-specific insights

    See more
    • Evolus Reports First Quarter 2025 Results

      Global Net Revenue of $68.5 Million for Q1 2025, Up 15.5% from Q1 2024 Meaningfully Outperformed Toxin Market Share Guidance Assumptions in Slower Market GAAP Operating Loss of $15.2 Million and Non-GAAP Operating Loss of $5.5 Million for the First Quarter; Remains On Track to Achieving Positive Non-GAAP Operating Income on a Consolidated Basis for the Full-Year 2025 Evolysse™ Launched in Q2 and Off to a Strong Start Reaffirms 2025 Net Revenue Guidance of $345 Million to $355 Million; Evolysse™ and Estyme® Injectable Hyaluronic Acid (HA) Gels Anticipated to Contribute 8 to 10% of Total Revenue for the Full-Year 2025 Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a

      5/7/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus to Report First Quarter Financial Results on May 7, 2025

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks. To participate in the conference call, dial (800) 579-2543 (U.S.) or (785) 424-1789 (international) or connect live via webcast on the Investor Relations page of the Evolus website here. Following the completion of the call, a telephonic replay

      4/23/25 8:00:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance

      Global Net Revenue Record of $79.0 Million for the Fourth Quarter and $266.3 Million for the Full-Year 2024, Representing 30% and 32% Growth Over the Prior Year, Respectively; Results Unchanged from January Preliminary Results GAAP Operating Loss Improved to $2.3 Million for the Fourth Quarter and $34.4 Million for the Full-Year 2024; Second Quarter of Profitability1 with Positive Non-GAAP Operating Income of $6.7 Million for Q4 2024 and Achieved Full-Year Profitability1 One Year Ahead of Expectations with Positive Non-GAAP Operating Income of $0.3 Million for FY 2024; On Track to Expanding Non-GAAP Operating Income Margins and Cash Generation Full-Year 2024 Non-GAAP Operating Expense

      3/4/25 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Evolus Inc.

      10-Q - Evolus, Inc. (0001570562) (Filer)

      5/7/25 5:02:48 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Evolus, Inc. (0001570562) (Filer)

      5/7/25 4:07:05 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Evolus, Inc. (0001570562) (Filer)

      5/5/25 4:08:09 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Moatazedi David sold $77,512 worth of shares (6,251 units at $12.40), decreasing direct ownership by 1% to 508,619 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      3/28/25 6:59:18 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Avelar Rui sold $369,868 worth of shares (27,904 units at $13.26), decreasing direct ownership by 7% to 362,467 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      3/20/25 6:27:35 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Beaver Sandra sold $119,243 worth of shares (8,996 units at $13.26), decreasing direct ownership by 5% to 173,583 units (SEC Form 4)

      4 - Evolus, Inc. (0001570562) (Issuer)

      3/20/25 6:27:25 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:50:28 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/14/24 4:00:06 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Evolus Inc.

      SC 13G/A - Evolus, Inc. (0001570562) (Subject)

      11/13/24 5:38:05 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EOLS
    Leadership Updates

    Live Leadership Updates

    See more
    • Evolus Announces Appointment of Albert G. White III to Board of Directors

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

      7/1/24 8:00:00 AM ET
      $COO
      $EOLS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

      Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that Nareg Sagherian has joined the Company as Vice President, Head of Global Investor Relations and Corporate Communications. In this role, Nareg will be responsible for interacting with current and prospective investors and managing a strategic investor relations and corporate communications program. Nareg will report to Sandra Beaver, Chief Financial Officer of Evolus. "I am thrilled to welcome Nareg to our team," said Sandra Beaver, Chief Financial Officer of Evolus. "Nareg's unique experience will enable him to drive a successful investor relati

      1/4/24 4:05:00 PM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

      Industry Leader Brings 20+ Years of Cosmetic Expertise to the Performance Beauty Category Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, has named Ms. Tomoko Yamagishi-Dressler as Chief Marketing Officer (CMO), effective today. Yamagishi-Dressler is an accomplished executive with more than two decades of established excellence leading omnichannel marketing for global beauty companies. A true strategist, Yamagishi-Dressler has successfully driven profitable business growth and increased equity for an iconic portfolio of industry brands. This press release features multimedia. View the full release here: https:

      8/21/23 8:45:00 AM ET
      $EOLS
      Biotechnology: Pharmaceutical Preparations
      Health Care